Hypersomnia

Beacon Biosignals Acquires Dreem, Launches At-home Sleep Monitoring Services for Clinical Trials

Retrieved on: 
Tuesday, July 11, 2023
DSM-IV codes, Actigraphy, Drug development, Sleep, Hypersomnia, Arnal, Schizophrenia, Clinical trial, Insomnia, Quality of life, Narcolepsy, Research, Brain, Biomarker, Disorder, Science, Neuropsychiatric Disease and Treatment, Acquisition, MD, Machine learning, EEG, Beacon, Alzheimer's disease, Medical device, Pharmaceutical industry, Medical imaging, Bad Dreems

Dreem, a market leader in developing clinically-validated sleep monitoring devices, is poised to markedly enhance Beacon's capabilities in data acquisition and clinical trial operations, creating substantial value for Beacon's biopharma partners.

Key Points: 
  • Dreem, a market leader in developing clinically-validated sleep monitoring devices, is poised to markedly enhance Beacon's capabilities in data acquisition and clinical trial operations, creating substantial value for Beacon's biopharma partners.
  • As part of this acquisition, Beacon Biosignals secured an undisclosed financing round with participation from its syndicate of Series A investors, led by General Catalyst.
  • At-home, longitudinal monitoring is positioned to progress the underlying science of sleep physiology beyond what is possible with limited assessments in an unnatural sleep lab setting.
  • Prominent sleep expert and Beacon Biosignals Scientific Advisory Board member, Dr. Andrew Krystal, MD, added, "Sleep plays a crucial role in neuropsychiatric diseases, and monitoring it in realistic, at-home settings is essential for understanding the full impact on patients.

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023

Retrieved on: 
Saturday, June 3, 2023
Idiopathic hypersomnia, Doctor of Philosophy, Food, IH, Drug, Narcolepsy, Hypersomnia, Beyond Sleep, Brain, FL, Sleep Research Society, Patient, Kleine–Levin syndrome, Somnolence, Associated, Orphan, SDX, FDA, Therapy, Sleep, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Conference, Caregiver, Disease, Pharmaceutical industry, Zebra

CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly Zevra.), a rare disease therapeutics company, today announced that an oral presentation featuring the Phase 2 clinical trial design evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, will be presented at the Hypersomnia Foundation’s 2023 Beyond Sleepy Conference being held June 2 - 4, 2023, in Indianapolis, IN, for people living with IH, narcolepsy and Kleine-Levin syndrome and their supporters. Zevra is a corporate sponsor of the Hypersomnia Foundation and the Beyond Sleep program.

Key Points: 
  • CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company, formerly Zevra.
  • Zevra is a corporate sponsor of the Hypersomnia Foundation and the Beyond Sleep program.
  • SDX was recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of IH.
  • Zevra has also opened an IND to study KP1077 for the treatment of narcolepsy.

MyndBlue Announces the Publication in Scientific Reports of the Discovery of a Predictive Biosignature in Major Depressive Disorder, Derived From Physiological Measurements of Outpatients Using Machine Learning

Retrieved on: 
Tuesday, April 25, 2023
Biotechnology, Health, Mental Health, Artificial Intelligence, Technology, Clinical Trials, Other Technology, Other Health, Patient, Bichat–Claude Bernard Hospital, Depression, Nature Portfolio, Life, Somatic symptom disorder, Disability, Anxiety, Respiratory rate, Sleep, Grammatical mood, Genetic disorder, Hope, Intelligence, Trial of the century, Hypersomnia, Insomnia, US, AP-HP, DSM-IV codes, MDD, Mood disorder, Post-traumatic stress disorder, Physician, Machine learning, Medicine, Scientific Reports, Pleasure, Artificial intelligence, AI, Mathematics, Heart rate, Research, Death, Psychomotor agitation, Medtech, PTSD, Fatigue, Disease, Medical device, Pharmaceutical industry, Nursing, Medical imaging

The article, published on April 25th under the title "Predictive biosignature of major depressive disorder derived from physiological measurements of outpatients using machine learning" in open access on the Scientific Reports website, is the first scientific publication addressing this discovery in a peer-reviewed journal.

Key Points: 
  • The article, published on April 25th under the title "Predictive biosignature of major depressive disorder derived from physiological measurements of outpatients using machine learning" in open access on the Scientific Reports website, is the first scientific publication addressing this discovery in a peer-reviewed journal.
  • When something difficult has happened, sad feelings and bad moods are a normal part of life.
  • The depressed patient may also experience anxiety, loss of appetite, insomnia or hypersomnia, low self-esteem and recurrent thoughts of death.
  • In order to address this issue, MyndBlue has sought to develop a machine learning algorithm that identifies a biosignature to provide a clinical score of the depressive symptoms using individual physiological measurements.

Biometrics Leader LifeQ Revolutionizes Healthcare with Disease Screening and Early Detection

Retrieved on: 
Monday, March 20, 2023
Mont Blanc, Fossil, Blood pressure, Medicine, Night, Probability, Photoplethysmogram, Cardiomyopathy, TAG Heuer, Health, Bradycardia, Classification, HOCM, Atrial fibrillation, Respiratory rate, COVID-19, Sleep, Restless legs syndrome, Arteriosclerosis, Narcolepsy, Sleep apnea, Acute (medicine), Tachycardia, Hypersomnia, Hypertension, Aortic stenosis, Insomnia, PLMD, Patient, Rapid eye movement sleep behavior disorder, Physician, Cardiovascular disease, PPG, Korea Disease Control and Prevention Agency, Diagnosis, Heart rate, Skin temperature, Chronic condition, Sleepwalking, Bigeminy, Conditional sentence, Disease, REM, Pharmaceutical industry, Medical device, Suunto

ATLANTA, March 20, 2023 /PRNewswire/ -- LifeQ, the company that uses globally-recognized watch brands to gather personalized, clinical-grade data, announced it can detect as many as 40 sleep and cardiovascular disorders with smart watches and other wearable devices, with an anticipated 100 diseases and disorders within the next two years—revolutionizing healthcare and improving consumers' lives. LifeQ co-founders Laurence (Laurie) Olivier, CEO, and Dr. Franco du Preez, Chief Science Officer, made the announcement.

Key Points: 
  • LifeQ co-founders Laurence (Laurie) Olivier, CEO, and Dr. Franco du Preez, Chief Science Officer, made the announcement.
  • LifeQ-enabled devices will help busy clinicians to detect important medical conditions, enable data-driven disease classification as well as facilitate disease prevention.
  • Screening for and flagging disease using wearables is possible through LifeQ's unique combination of photoplethysmography (PPG) and computational systems biology approach.
  • Wearable devices will soon enable insights for hundreds of diseases, providing a personalized action plan and a truly preventative approach to healthcare.

KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

Retrieved on: 
Wednesday, January 18, 2023
Disease, Caregiver, MFA, CNS, Sleep disorder, IH, Safety, Knowledge, Idiopathic hypersomnia, Partnership, Central nervous system, KMPH, Therapy, Patient, Glycogen storage disease, Hypersomnia, Sleep, Neurodegeneration, Pharmaceutical industry

IH is a chronic neurologic disorder marked by significant detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.

Key Points: 
  • IH is a chronic neurologic disorder marked by significant detrimental effects on nighttime sleep as well as daytime sleepiness/wakefulness.
  • KemPharm expects to enroll approximately 48 adult patients with IH in more than 30 centers in the United States.
  • “IH is a rare sleep disorder for which few treatment options exist.
  • “Support from sponsors like KemPharm are key to our efforts to advocate for and support those dealing with debilitating sleep disorders.”

Arthex announces regulatory milestones met in its program to develop ATX-01 in Myotonic Dystrophy Type 1

Retrieved on: 
Wednesday, December 14, 2022
Chemistry, DM1, Industrial technology, Drug discovery, Scientific Advice Mechanism, Development, Food, IND, Muscle, EMA, Toxicology, Patient, Orphan drug, Myotonic dystrophy, Disease, FDA, Fatigue, CMC, CTA, MicroRNA, ODD, European Medicines Agency, Hypersomnia, Science, CDTI, Tissue, Food and Drug Administration Amendments Act of 2007, FIH, Centre for the Development of Industrial Technology, Pharmaceutical industry

Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.

Key Points: 
  • Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.
  • Myotonic dystrophy type 1 (DM1) is a highly disabling disease affecting more than one million people worldwide.
  • Arthex Biotech is a preclinical-stage drug development company focused on improving the lives of patients with high unmet medical needs.
  • Arthex Biotech's investors are Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI).

Arthex announces regulatory milestones met in its program to develop ATX-01 in Myotonic Dystrophy Type 1

Retrieved on: 
Wednesday, December 14, 2022
Chemistry, DM1, Industrial technology, Drug discovery, Scientific Advice Mechanism, Development, Food, IND, Muscle, EMA, Toxicology, Patient, Orphan drug, Myotonic dystrophy, Disease, FDA, Fatigue, CMC, CTA, MicroRNA, ODD, European Medicines Agency, Hypersomnia, Science, CDTI, Tissue, Food and Drug Administration Amendments Act of 2007, FIH, Centre for the Development of Industrial Technology, Pharmaceutical industry

Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.

Key Points: 
  • Importantly, no red flags or concerns were raised regarding the toxicology or rationale to support a FIH study.
  • Myotonic dystrophy type 1 (DM1) is a highly disabling disease affecting more than one million people worldwide.
  • Arthex Biotech is a preclinical-stage drug development company focused on improving the lives of patients with high unmet medical needs.
  • Arthex Biotech's investors are Invivo Capital, AdBio Partners, and the Centre for the Development of Industrial Technology (CDTI).

The Worldwide Narcolepsy Therapeutics Industry is Expected to Reach $5 Billion by 2028 at a 10.5% CAGR - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
General Health, Pharmaceutical, Health, Investment, Sodium oxybate, Gamma-Hydroxybutyric acid, Narcolepsy, Hypersomnia, Economic development, Excessive daytime sleepiness, Insomnia, Modafinil, Life, Pharmacokinetics, Dopamine, Person, Emotion, Stimulant, NIH, Hypnagogia, EDS, National Institute for Health and Care Excellence, Cataplexy, Union, Restless legs syndrome, Sleep apnea, Norepinephrine, Sleep paralysis, GABAB, Diagnosis, Health, Patient, Pharmaceutical industry

The Global Narcolepsy Therapeutics Market size is expected to reach $5 billion by 2028, rising at a market growth of 10.5% CAGR during the forecast period.

Key Points: 
  • The Global Narcolepsy Therapeutics Market size is expected to reach $5 billion by 2028, rising at a market growth of 10.5% CAGR during the forecast period.
  • Modafinil, armodafinil, and stimulants are only a few of the medications used to treat narcolepsy.
  • Others include sodium oxybate and venlafaxine, which are used to treat the symptoms of sleep paralysis and sleep-related hallucinations (e.g.
  • One of the main factors holding back the narcolepsy market is the high cost of narcolepsy diagnosis and treatment.

Avidity Biosciences Engages with Patient Communities During National Muscular Dystrophy Awareness Month as part of Commitment to Developing Muscular Dystrophy Programs

Retrieved on: 
Wednesday, September 7, 2022
People, Muscle weakness, DMPK, COVID-19, Fatigue, Muscle, SAN, Awareness, AOC, Science, U.S. Securities and Exchange Commission, Twitter, MDF, RNA transfection, FSHD, Patient, Global Genes, Caregiver, Cardiac muscle, Degenerative disease, Protein, SEC, Myotonic dystrophy, Nasdaq, Tears, Myotonia, Security (finance), RNA, Antibody-oligonucleotide conjugate, Disease, Avidity, Duchenne, Muscular dystrophy, LinkedIn, DUX4, Lists of diseases, DMD, Facioscapulohumeral muscular dystrophy, Private Securities Litigation Reform Act, Mortality, AOCS, Weakness, Life expectancy, Tissue, IND World's Fair Line, Learning, Duchenne muscular dystrophy, Hypersomnia, Conference, DM1, Therapy, Face, Vaccine, Pharmaceutical industry, Medical device, Dietary supplement

SAN DIEGO, Sept. 7, 2022 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), honors National Muscular Dystrophy Awareness Month, an annual observance that raises awareness for families across the nation who are living with neuromuscular diseases. This month Avidity will also raise awareness and support patient-focused activities for World Duchenne Awareness Day on September 7 and International Myotonic Dystrophy Awareness Day on September 15. Avidity is on track to have three rare muscular dystrophy programs in the clinic by the end of this year for myotonic dystrophy type 1 (DM1), Facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD).

Key Points: 
  • This month Avidity will also raise awareness and support patient-focused activities for World Duchenne Awareness Day on September 7 and International Myotonic Dystrophy Awareness Day on September 15.
  • Avidity is on track to have three rare muscular dystrophy programs in the clinic by the end of this yearfor myotonic dystrophy type 1 (DM1), Facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD).
  • "We look forward to engaging with patient communities and their families this month to better understand their unique journeys and experiences.
  • We are on track to have three rare muscular dystrophy programs in the clinic by the end of this year."

Nox Health Announces New Partnership With Totem Employee Benefits Services

Retrieved on: 
Wednesday, June 1, 2022
Cloud, A Sleeping Life, Restless legs syndrome, Nox, Adult, Health, Hypersomnia, Partnership, Organization, Somnolence, Physician, GLOBE, Patient, Technology, Sleep, Health insurance, Medicine, Totem

ATLANTA, June 01, 2022 (GLOBE NEWSWIRE) -- Nox Health , the global sleep health leader committed to helping people wake up to a brighter world, has partnered with Totem , a benefits consulting service that provides a holistic and personalized approach to employee benefits.

Key Points: 
  • ATLANTA, June 01, 2022 (GLOBE NEWSWIRE) -- Nox Health , the global sleep health leader committed to helping people wake up to a brighter world, has partnered with Totem , a benefits consulting service that provides a holistic and personalized approach to employee benefits.
  • The two companies will collaborate to bring sleep health education and resources to employees and adult dependents on the Totem Health Plan powered by SleepCharge by Nox Health.
  • The SleepCharge by Nox Health program offers sleep health education and resources, as well as access to sleep health professionals and best-in-class treatment for those with sleep problems.
  • Totem has chosen SleepCharge by Nox Health to help our clients improve their overall health through better sleep, said Schultz.